The consumption of cacao products rich in (-)-epicatechin associates with reduced cardiovascular risk and improved vascular function. However, little is known about (-)epicatechin effects on aged endothelium. In order to characterize the health restoring effects of (-)-epicatechin on aged endothelium and identify underlying mechanisms, we utilized high passage number (i.e. aged) bovine coronary artery endothelial cells and aortas of 3 and 18 month old rats.
Introduction
Cardiovascular diseases (CVD) are a prominent, worldwide cause of morbidity and mortality. It is well recognized that the health of the endothelium is central to the underlying pathophysiology of many CVD and that aging is an important contributor to the development of endothelial dysfunction (1, 2) . The identification of safe and effective agents that can promote the preservation and/or restoration of endothelial health is thus, of high priority as their use may reduce CVD incidence.
Central to the preservation of vascular health, is the endothelial nitric oxide synthase (eNOS), which under physiological conditions is responsible for the production of nitric oxide (NO) (3) .
It has been demonstrated that vascular and endothelial cell function deteriorates with aging and it appears to be mainly due to a decrease in NO bioavailability (4) . The causes for reduced bioavailability of NO as a function of aging are not completely understood. However, the acetylation of specific amino acid residues present in eNOS can trigger the loss of function by interfering with their phosphorylation (3) . Aging is known to correlate with higher protein acetylation levels and loss of sirtuin-1 deacetylation activity, which may partly underlie decreased eNOS activity (5, 6) .
The stimulation of NO synthesis by flavonoid-containing compounds has received widespread attention, as their effects appear to reduce CVD. (7, 8) . Epidemiological studies indicate that the regular intake of cacao derived products such as dark chocolate, is inversely associated with the incidence of CVD including myocardial infarction, heart failure and stroke (9) (10) (11) . We have reported on the capacity of the most abundant cacao flavanol, (-)-epicatechin (Epi) to stimulate the production of NO and ascribed this effect to the ability of the flavanol to increase eNOS protein expression and activity levels (12, 13) . We have also reported on the capacity of Epi to Page 3 of 34 Food & Function notably mitigate markers of tissue aging and mitochondrial deterioration in senile mice (14) . So far, no studies have examined the effects of Epi on aged endothelium NOS/NO levels and determine its ability to restore mitochondrial number and function.
With these goals in mind, we evaluated the effects of Epi on markers of cell senescence, NO production (via eNOS), acetylation levels, mitochondrial biogenesis and function as well as vasodilatory responses using bovine coronary artery endothelial cells and aortas isolated from and NaOH, which enhances the detection of the fluorescent product, 1(H)-naphthotriazole.
Measurement of the fluorescence generated is quantified using a fluorometer (FLx800 Bio-Tek Instruments). Nitrate/nitrite values were normalized by total protein after the cells were scrapped from the plate and lysed as described previously. Plasma (50 µl) was collected from treated animals (see below) and NO levels measured as above.
Senescence associated β-galactosidase activity
Young and aged cells were grown in 12 and 96 well-plates. At 80% confluence, cells were treated for 48 h (control, Epi, Epi-L-NAME, and L-NAME). After the 48 h treatment, βgalactosidase activity was determined using a senescence associated β-galactosidase staining kit.
The cells in the 12 well plates were used for visualizing the characteristic blue staining of βgalactosidase activity under the microscope and images were taken. The cells in the 96 well plate were used for measuring β-galactosidase activity via colometric analysis in a spectrophotometer (µQuant, Bio-Tek Instruments, Inc.).
Western Blot
In order to examine aging markers, eNOS/NO pathway, and mitochondrial related proteins,
Western blotting was performed. Cells were treated as described above. After treatment, cells were lysed and total protein was extracted. A total of 30 µg of protein was loaded onto a 4-15% gel, electrotransferred, incubated for 1 h and followed by either 1-3 h incubation at room temperature or overnight incubation at 4°C with primary antibodies. Primary antibodies were typically diluted 1:1,000 or 1:2,000 in buffer plus 5% bovine serum albumin or 2 % nonfat milk.
Membranes were washed (3 X for 5 min) in buffer and incubated 1 h at room temperature in the presence of conjugated secondary antibodies diluted 1:5,000 in blocking solution. Membranes were again washed three times in buffer and immunoblots were developed. Band intensities were digitally quantified and normalized by β-tubulin.
Protein acetylation measurements
Immunoprecipitation was used to selectively isolate eNOS and quantify its acetylation status.
Treated cells were lysed, total protein extracted, and protein content measured in the supernatant by Bradford method. A total of 0.5 mg protein was precleared by adding 1 µg of normal rabbit IgG control and 20 µL protein agarose and mixed for 30 min (4°C) with subsequent centrifugation at 12,000 g for 10 min at 4°C. The supernatant was recovered and incubated at 4° C under mild agitation for 3 h with 10 µL of eNOS immunoprecipitation antibody. Twenty µl of protein A/G-sepharose was added, and the mixture was incubated overnight at 4 °C with shaking. The immunoprecipitation mixture was centrifuged at 12,000 g for 15 min at 4°C and the supernatant recovered and stored at 4°C for later analysis. The pellet was washed 3 X with extraction buffer under shaking 15 min and centrifuged at 12,000 g for 15 min at 4°C. The immunoprecipitation proteins in the pellet and those remaining in the supernatant were applied to a precast 4-15% sodium dodecyl sulfate-polyacrylamide gradient gel electrophoresis for Westerns against acetylated-lysine and sirtuin-1.
Mitochondrial complex II and IV
Complex II and IV protein content was evaluated in cells using a MitoBiogenesis kit. Cells were seeded onto 96 well plates (50,000/well) and cultured using standard media. Cells were incubated with vehicle, Epi, Epi and L-NAME, and L-NAME for 48 h. Cells were washed with buffer and fixed with 4% formaldehyde followed by washes with buffer. Cells were exposed to 0.5% acetic acid for 5 min to block endogenous alkaline phosphatase activity followed by washes with buffer and exposure to a permeabilization buffer for 30 min. Cells were exposed to a blocking solution and incubated with primary antibodies overnight at 4 o C, followed by rinsing with wash buffer and incubation with secondary antibodies labeled with alkaline phosphatase and horseradish peroxidase for 2 h. Developing solutions (alkaline phosphatase for complex II and horseradish peroxidase for complex IV) were added and kinetic colorimetric signals measured in a spectrophotometer (µQuant, Bio-Tek Instruments, Inc.) using 405 nm for complex II and 600 nm for IV. Total absorbance values were normalized against cell number as derived from the use of Green Janus staining.
Citrate synthase activity (CS)
After 48 h of treatment, cells were lysed and total protein was extracted. An amount of 20 µg of protein was used for the assay. CS activity was determined by immunocapture using a citrate synthase kit in a 96 well plate according to manufacturer's instructions. The activity of the enzyme captured in the wells was determinated by color development at 412 nm. All samples were tested in duplicates and activity measured at room temperature.
Mitotracker Green Assay
Mitochondria were labeled using the cell-permeable probe Mitotracker Green FM dye. Cells were plated in 96-well plates (1 × 10 4 cells/well). After 24 h of incubation with growth media, cells were incubated with Epi, Epi and L-NAME, and L-NAME for 48 h. Cells were washed with 100 µL serum-free DMEM and stained with 200 nM Mitotracker Green FM dissolved in Hank's Buffered Saline Solution for 30 min. Unstained control cells were incubated with serumfree media containing no dye but treatment or vehicle as the stained samples. After staining, cells were washed three times with 100 µL serum-free media and thereafter 100 µL of buffer was added to each well. For the microplate assay, staining was detected on a fluorescence microplate reader (µQuant from Bio-Tek instruments) (excitation 485 nm, emission 520 nm), and fluorescence was subtracted from the unstained control and expressed relative to cell number. 
Animals

Blood pressure
A non-invasive method to measure systolic blood pressure was employed by using a pressure transducer placed on the tail of the animals with values digitally recorded.
Vascular reactivity
Under anesthesia (pentobarbital 60 mg/kg) animals were decapitated and the thoracic aorta from the diaphragm to the aortic arch isolated. Aortas were immediately submerged in cold Krebs solution to remove all adjacent connective tissue, then cut into ring segments (4-5 mm long), which were then mounted on two stainless steel hooks within an isolated organ chamber. 
Immunofluorescence
In order to detect post-translational modifications (phosphorylation and acetylation) on eNOS in aging, we used immunofluorescence staining of dissected aortas from young and aged rats.
Aortas were cut into 0.5 cm fragments. Each vessel fragment was filled with tissue freezing medium and frozen in liquid nitrogen-isopentane. Cryosections (7 µm in thickness) from each vessel were permeabilized for 3 min with 0.3% Triton X-100. After incubation with blocking solution (5% bovine serum albumin in phosphate-buffered solution [PBS]) for 1 h at room temperature, cryosections were incubated for 3 h with one primary antibody (single staining) or two primary antibodies (double staining) at room temperature. After several washes, sections were incubated with a fluorescent secondary antibody for 1 h at room temperature. After rinsing with buffer, sections were mounted using Vectashield medium, counterstained to visualize nuclei (Vector Laboratories, Burlingame, Calif., USA) and observed using a fluorescence microscope.
Data Analysis
For cell culture experiments, at least three independent experiments each in triplicate were performed. For animal studies, six rats per group were included. Results are expressed as a mean ± standard error of the mean (SEM). Data analysis was performed by one-way analysis of variance (ANOVA) followed by Tukey's post hoc test using GraphPad Prism (GraphPad Software Inc., San Diego, USA). A p value of <0.05 was considered to be statistically significant.
Results
Figure 1A denotes β-galactosidase staining observed in young and aged cells while figure 1B reports on their quantification using 96 well stained plates. At baseline, increased staining levels are observed in aged vs. young cells, which were reduced by Epi treatment. The use of L-NAME in untreated aged cells further increased staining and was able to block the effects of Epi. In young cells, Epi and/or L-NAME treatments did not apparently alter β-galactosidase staining. As illustrated in figure 1C , a similar pattern of changes was observed in β-galactosidase protein levels measured by Western blot whereby young cells evidence low levels of staining regardless of the treatment applied. Aged cells demonstrated significantly higher protein levels vs. young and Epi treatment suppressed these increases. Figure 2A and B report on the effects triggered by aging and treatments on NO and p-eNOS levels respectively. Treatment of young cells with Epi significantly increased NO levels. With aging, cells evidenced significantly reduced (~40%) NO levels and Epi was able to restore NO levels to those of young cells. p-eNOS results essentially paralleled those noted for NO levels. Figure 3A and B shows the effects of aging on sirtuin-1. In young cells, Epi stimulated the phosphorylation of sirtuin-1 by ~40%. Aging led to a decrease of ~50% in p-sirtuin-1 levels which were restored to those of young cells with Epi. Figure 4A reports on the total protein acetylation levels of young vs. aged cells. While no differences were noted in young cells, aging led to ~3 fold increase in total protein acetylation which was essentially normalized with Epi treatment. Figure 4B and 4C plots eNOS acetylation levels in young and aged cells as well as the levels of sirtuin-1that were associated with eNOS following immunoprecipitation. While no effects were noted in young cells, eNOS acetylation essentially doubled in aged cells and was partially restored to young cell levels by Epi treatment. Sirtuin-1 levels associated with eNOS decreased by ~60% in aged cells and were essentially restored to those of young cells by Epi treatment. Figure 5A and 5B illustrates the effects of aging and treatments on markers of mitochondrial biogenesis, cristae and oxidative phosphorylation (TFAM, mitofilin, and complex V). In young cells, an increase of ~25% was noted with Epi treatment in all proteins. Aging led to ~50% reduction in the protein levels and treatment with Epi, fully restored levels to those of young cells. Figure 6A /B reports on the effects of aging and treatment on oxidative phosphorylation complexes II and IV. In young cells, a stimulation was induced with Epi. Aged cells have a decrease of ~30% in protein levels that were fully restored by Epi. Figure 6C Figure 7A reports on systolic blood pressure levels in young and aged rats and 7B on corresponding plasma NO levels detected. Aged animals evidenced higher systolic pressures (~130 vs. 100 mmHg, aged vs. young) and Epi treatment was able to normalize their levels to those of young rats. In aged animals, plasma NO levels were reduced by ~50% and Epi was able to restore them to those of young rats (while also significantly stimulating them in this group). Figure   8A and B denote p-eNOS levels as detected from immunofluorescent staining of aortic endothelium in the same animals evidencing parallel results to those noted for NO levels. Panel 8C illustrates eNOS and total protein acetylation staining levels in the endothelium of aortas of young and aged rats. With aging, a reduction in total eNOS levels were noted while total protein acetylation increased. Epi treatment was able to increase eNOS levels while reducing total protein acetylation in endothelial cells.
Discussion
Results indicate that in aged endothelium, a reduction in NO production occurs which is associated with decreased eNOS phosphorylation at activation sites coupled to higher levels of amino acid residue acetylation. Aged endothelium also evidences decreased levels for regulators of mitochondria biogenesis including sirtuin-1 and organelle function. Epi restored aged endothelium and rat NO production to levels comparable to those of young cells/animals. Effects were associated with increased levels of eNOS phosphorylation, reduced acetylation, and improved mitochondrial function. These results follow the ability of Epi to restore sirtuin-1 protein levels and deacetylase activity and thus, mitigate aging induced loss of vascular function.
The restoration of physiological levels of NO to those comparable of a younger phenotype is seen as an appealing strategy to mitigate CVD development. Recommended strategies include aerobic exercise and intake of foods rich in dietary nitrates such as beetroot juice. (15) (16) (17) (18) .
However, exercise activity may be difficult to maintain in particular, later in life. Natural supplements such as resveratrol have been considered and tested with modest to null results. (19) (20) (21) . Interestingly, there is a greater level of recognition for the pleiotropic effects of statins, which include positive effects on the eNOS regulatory system (22) . However, statin use (beyond cholesterol reducing effects) remains controversial in particular, since a large percentage of the population is opposed to consuming drugs for possibly decades where the adverse effects of such compounds may also become evident (myopathy and type 2 diabetes) (23, 24) . The use of androgen precursors and estrogen supplementation has also been considered to mitigate vascular inflammation and/or restoring function (25, 26) . However, the use of hormone supplementation remains controversial (27) .
Epidemiological studies associate cocoa product consumption with reduced cardiometabolic risk (28, 29) . Clinical studies using cocoa products document positive effects on vascular structure and/or function in menopausal women, smokers and those with ischemic heart disease (30, 31) .
Studies also demonstrate that cocoa consumption can mobilize angiogenic cells (32) and improve memory following 3 months of supplementation in normal 60-year-old subjects while increasing brain blood volume (33) . Evidence has been generated regarding the mechanisms that may underlie the vascular effects of Epi. We demonstrated that human coronary artery endothelial cells treated with 1 µM Epi, stimulates serine 633 and 1177 eNOS phosphorylation and the dephosphorylation at threonine 495 thus, activating the enzyme. Epi also promotes eNOS uncoupling from caveolin-1 via its interaction with heat shock protein 90 and binding to calmodulin-1 leading to its activation (12) . Furthermore, we reported on Epi's unique ability to induce eNOS activation in a calcium independent manner (13) . We also established that eNOS amino acid residue glycosylation levels are higher (yielding enzyme inactivation) in obese mice and human coronary artery endothelial cells exposed to high glucose and that Epi is able to reduce these to those of control samples (34) . These results demonstrate the versatility of this compound in its ability to activate eNOS and thus, restore age-related NO decline via nonredundant actions.
An accepted marker of cell aging is β-galactosidase activity (35) . In this study, β-galactosidase activity increased with cell passage number and Epi treatment mitigated the effect. The use of L-NAME further aggravated β-galactosidase activity differences noting the dependence of cell aging on NO. Aging of cells led to a diminished capacity to produce NO, which correlated closely with reduced levels of eNOS phosphorylation. Epi treatment was able to restore NO and eNOS phosphorylation levels to those similar of young cells. These effects, are comparable to those reported for statins in human umbilical cord endothelial cells aged with hydrogen peroxide treatment (36) .
Results indicate that loss of sirtuin-1 mediated deacetlyase activity underlies at least in part, aging induced loss of eNOS function. A reduced level of sirtuin-1 activity may be secondary to decreases in protein levels and/or its phosphorylation. Here, we report on the capacity of Epi to restore sirtuin-1 protein and phosphorylation levels effects, that can also be triggered by agents such as statins and resveratrol (36, 37) . Aging is also associated with higher eNOS acetylation, an effect that was also suppressed by Epi treatment and was linked to the enhanced protein-protein interaction of eNOS with sirtuin-1. As reported by Ota et al, statins also increase sirtuin-1 expression and its physical coupling to eNOS (36) .
In close association to the health status of the endothelial cells, are the indicators of mitochondrial structural integrity and function. In our study, we assessed protein levels for a recognized regulator of mitochondrial biogenesis (TFAM), cristae structure (mitofilin), oxidative phosphorylation (complex V) and function (CS activity) including indicators of mitochondrial biogenesis markers (complex II/IV) and abundance (mitotracker green). In all cases, aging depleted the levels of these endpoints, which were fully restored by Epi. Thus, treatment with Epi appears to reinstate the metabolic oxidative capacity of the cells to that comparable to young ones. The coupling of increases in mitochondria abundance, structure and function in endothelial cells to enhanced NO levels has also been demonstrated using resveratrol and statins (36, 38) . As demonstrated by Nisoli et al, NO effects appear partly dependent on increases in cyclic guanosine monophosphate and induction of peroxisome proliferator-activated receptor γ coactivator 1α as mitochondrial biogenesis induced by exposure to cold was markedly reduced in brown adipose tissue of eNOS null-mutant mice, which had a reduced metabolic rate and accelerated weight gain vs. wild-type mice (39) .
Crucial to support our in vitro were responses triggered by Epi in vivo. In aged rats, an increase in blood pressure was noted suggesting an increased stiffness and/or endothelial dysfunction, which was corroborated with decreased acethylcholine-induced vasodilation. Epi partly restored the functional responses (blood pressure and vasodilation) to those noted in young animals and these changes correlated with enhanced endothelial eNOS phosphorylation and reduced acetylation. A limitation to this study relates to the fact that when Epi is provided orally it is readily metabolized and Epi metabolites can reach "high" levels in blood and trigger similar effects on endothelium to the native molecule (40) . Ultimately, in the in vivo setting, the additive role of each chemical entity (including native Epi) likely accounts for the "final" response noted after the flavanol is provided orally. This scenario is not distinct from that given by the use of drugs such as losartan in cell culture where the metabolites that are generated in vivo are as or more potent than the native compound (41) .
Beyond endothelium effects, our group has published a series of studies documenting the positive impact that either cocoa or Epi can provide. In rodent models of myocardial infarction, obesity/insulin resistance and aging we have documented the protective effects that 1 mg/kg/day of Epi triggers on multiple endpoints and in many organs. Treatment reduces infarct size, stimulates angiogenesis, ameliorates obesity-induced indicators of cardiometabolic dysregulation, improves multiple indicators of oxidative stress, mitochondrial, skeletal and cardiac structure function in normal and aged animals (14, 34, (42) (43) (44) (45) . In proof of concept studies, cocoa supplementation (that yields blood levels similar to those of 1 mg/kg/day of Epi ~ 300 nM) improves multiple indicators of skeletal muscle structure and function (including NOS and NO levels) in patients with heart failure and type 2 diabetes (46) . In normal, sedentary subjects cocoa supplementation enhances multiple indicators of muscle metabolism while improving organ function (47) . Epi can also increase muscle strength in normal subjects and significantly reduce triglyceride levels in those with hypertriglyceridemia (48, 49) . A common central theme underlying Epi effects, are improvements in NO levels and stimulation of mitochondria.
In conclusion, we demonstrate that a compound found in high concentrations in cocoa 
